Skip to content

Author

P. Guedeney

We have 4 of 206 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Left atrial appendage occlusion for atrial fibrillation–related stroke despite chronic oral anticoagulation

Data on the benefit of percutaneous left atrial appendage occlusion (LAAO) in patients with atrial fibrillation (AF) who experience stroke despite chronic oral anticoagulation (OAC) are limited and not always consistent. To evaluate the association between LAAO and recurrent stroke or mortality using a pre...

L. Giovachini, J. Mesnier, T. Pommier et al. · 0 citations
Open access Oct 2026

In-hospital complications after left atrial appendage occlusion and their impact on long-term mortality: a multicenter study

Left atrial appendage occlusion (LAAO) is increasingly performed in patients with atrial fibrillation at high thromboembolic risk and contraindicated to long-term oral anticoagulation due to major bleeding risk. However, the incidence, determinants, and prognostic impact of in-hospital complications remain incomp...

T. Pommier, C. Lamarre, L. Giovachini et al. · 0 citations
Review Aug 2026

Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.

In stable patients with previous myocardial infarction, left ventricular ejection fraction ≥40%, no heart failure, and no other indication for β-blocker therapy, discontinuation met the non-inferiority criteria for the primary and key secondary endpoints.

J. Silvain, Ki H. Choi, Victorien Monguillon et al. · 1 citation
Open access Aug 2026

LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial.

In patients with acute MI undergoing PCI, first-line evolocumab combined with high-intensity lipid-lowering therapy produced rapid and sustained LDL-C reduction, with more than 80% of patients reaching the guideline-recommended target at 1 year.

G. Montalescot, E. Ferrari, G. Souteyrand et al. · 3 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.